Stockpolly
Search
Delisting risk
KAPA · AMEX · Biotechnology

Kairos Pharma (KAPA)

Develops resistance-focused cancer therapies led by ENV-105.

$1.66
Pre-market+0.05 (+3.04%)
At close$1.61(−2.42%)
Watchlist

Something off on this page? Send us feedback.

Next report
Nov 13, 2026
estimated · in 71 days
EPS estimate
−$0.56
Revenue estimate
—
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25Apr '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.09−$0.08−$0.08−$0.07−$0.07−$0.08−$0.06Pending
Estimate−$0.06−$0.05−$0.06−$0.10−$0.02−$0.07−$0.09−$0.56
Surprise−43.8%−60.0%−33.3%+30.0%−275.3%−14.3%+33.3%—

RevenueReportedEstimate

Feb '25Apr '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————

History

DateEstimateReportedSurprise
Nov 2026−$0.56——
Aug 2026−$0.09−$0.06+33.3%
May 2026−$0.07−$0.08−14.3%
Mar 2026−$0.02−$0.07−275.3%
Nov 2025−$0.10−$0.07+30.0%

The latest year is open to everyone — the 14 quarters behind it read with an account.

Sign in
Aug 2025
Apr 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 13, 2026−$0.56——————
Aug 12, 2026−$0.09−$0.06+33.3%———−2.0%
May 13, 2026−$0.07−$0.08−14.3%———+5.9%
Mar 31, 2026−$0.02−$0.07−275.3%———+3.6%
Nov 14, 2025−$0.10−$0.07+30.0%———−6.4%

The latest year is open to everyone — the 14 quarters behind it read with an account.

Sign in
Aug 12, 2025
Apr 15, 2025
Feb 26, 2025
Nov 14, 2024
Aug 16, 2024
May 13, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022